Creative Medical Technology Holdings Nasdaq/NYSE Compliance Notice
Creative Medical Technology Holdings received a deficiency notice from Nasdaq on November 10, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until May 10, 2027, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days. The notice has no immediate impact on the listing of the company's common stock (CELZ).
Creative Medical Technology Holdings reported a net loss of $5.59 million for the nine months ended September 30, 2026, driven by increased research and development and SG&A expenses. The company remains in a pre-revenue stage for the current period, though it successfully raised approximately $4.06 million through warrant exercises and stock sales to support its regenerative therapy pipeline.
Creative Medical Technology Holdings M&A Deal with BioDefense, Inc.
Creative Medical Technology Holdings acquired 4,000,000 shares of BioDefense, Inc. from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own common stock. Following the transaction, the company owns 80% of BioDefense, Inc., making it a majority-owned subsidiary.